Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash to Debt 29.85
NXTM's Cash to Debt is ranked higher than
69% of the 197 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.70 vs. NXTM: 29.85 )
Ranked among companies with meaningful Cash to Debt only.
NXTM' s Cash to Debt Range Over the Past 10 Years
Min: 0.5  Med: 4.07 Max: No Debt
Current: 29.85
Equity to Asset 0.63
NXTM's Equity to Asset is ranked higher than
53% of the 190 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 0.61 vs. NXTM: 0.63 )
Ranked among companies with meaningful Equity to Asset only.
NXTM' s Equity to Asset Range Over the Past 10 Years
Min: -4.58  Med: 0.61 Max: 0.89
Current: 0.63
-4.58
0.89
F-Score: 5
Z-Score: 4.66
M-Score: -2.60
WACC vs ROIC
1.10%
-10.87%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating margin (%) -4.35
NXTM's Operating margin (%) is ranked lower than
66% of the 193 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 5.20 vs. NXTM: -4.35 )
Ranked among companies with meaningful Operating margin (%) only.
NXTM' s Operating margin (%) Range Over the Past 10 Years
Min: -406.41  Med: -19.64 Max: -4.63
Current: -4.35
-406.41
-4.63
Net-margin (%) -4.56
NXTM's Net-margin (%) is ranked lower than
64% of the 193 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.71 vs. NXTM: -4.56 )
Ranked among companies with meaningful Net-margin (%) only.
NXTM' s Net-margin (%) Range Over the Past 10 Years
Min: -408.41  Med: -23.47 Max: -6.26
Current: -4.56
-408.41
-6.26
ROE (%) -8.09
NXTM's ROE (%) is ranked lower than
68% of the 190 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.62 vs. NXTM: -8.09 )
Ranked among companies with meaningful ROE (%) only.
NXTM' s ROE (%) Range Over the Past 10 Years
Min: -491.86  Med: -33.44 Max: -8.69
Current: -8.09
-491.86
-8.69
ROA (%) -5.02
NXTM's ROA (%) is ranked lower than
65% of the 199 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.86 vs. NXTM: -5.02 )
Ranked among companies with meaningful ROA (%) only.
NXTM' s ROA (%) Range Over the Past 10 Years
Min: -47.99  Med: -17.19 Max: -5.02
Current: -5.02
-47.99
-5.02
ROC (Joel Greenblatt) (%) -11.75
NXTM's ROC (Joel Greenblatt) (%) is ranked lower than
67% of the 197 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 10.00 vs. NXTM: -11.75 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
NXTM' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -357.6  Med: -66.04 Max: -20.17
Current: -11.75
-357.6
-20.17
Revenue Growth (3Y)(%) 6.80
NXTM's Revenue Growth (3Y)(%) is ranked higher than
60% of the 156 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.80 vs. NXTM: 6.80 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
NXTM' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: 24.90 Max: 332.9
Current: 6.8
0
332.9
EBITDA Growth (3Y)(%) -13.00
NXTM's EBITDA Growth (3Y)(%) is ranked lower than
83% of the 133 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 6.90 vs. NXTM: -13.00 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
NXTM' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -61.9  Med: -31.65 Max: 1.5
Current: -13
-61.9
1.5
EPS Growth (3Y)(%) -0.60
NXTM's EPS Growth (3Y)(%) is ranked lower than
61% of the 132 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.70 vs. NXTM: -0.60 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
NXTM' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -34.5  Med: -27.00 Max: 1.1
Current: -0.6
-34.5
1.1
» NXTM's 10-Y Financials

Financials (Next Earnings Date: Est. 2016-05-06)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2015

NXTM Guru Trades in Q1 2015

Steven Cohen 994,705 sh (+100.87%)
RS Investment Management 2,477,574 sh (+7.67%)
Jim Simons 57,190 sh (-54.96%)
» More
Q2 2015

NXTM Guru Trades in Q2 2015

Paul Tudor Jones 16,200 sh (New)
RS Investment Management 3,601,254 sh (+45.35%)
Steven Cohen 1,269,600 sh (+27.64%)
Steven Cohen 600,000 sh (unchged)
Jim Simons Sold Out
» More
Q3 2015

NXTM Guru Trades in Q3 2015

Jim Simons 295,490 sh (New)
RS Investment Management 4,087,651 sh (+13.51%)
Paul Tudor Jones Sold Out
Steven Cohen 993,500 sh (-21.75%)
» More
Q4 2015

NXTM Guru Trades in Q4 2015

Jim Simons 361,990 sh (+22.50%)
RS Investment Management 3,775,059 sh (-7.65%)
Steven Cohen 598,300 sh (-39.78%)
» More
» Details

Insider Trades

Latest Guru Trades with NXTM

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 5.41
NXTM's P/B is ranked lower than
79% of the 188 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.68 vs. NXTM: 5.41 )
Ranked among companies with meaningful P/B only.
NXTM' s P/B Range Over the Past 10 Years
Min: 0.8  Med: 4.41 Max: 14.23
Current: 5.41
0.8
14.23
P/S 3.09
NXTM's P/S is ranked lower than
55% of the 192 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.49 vs. NXTM: 3.09 )
Ranked among companies with meaningful P/S only.
NXTM' s P/S Range Over the Past 10 Years
Min: 0.64  Med: 3.55 Max: 15.95
Current: 3.09
0.64
15.95
EV-to-EBITDA 69.55
NXTM's EV-to-EBITDA is ranked lower than
91% of the 133 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 16.31 vs. NXTM: 69.55 )
Ranked among companies with meaningful EV-to-EBITDA only.
NXTM' s EV-to-EBITDA Range Over the Past 10 Years
Min: -1804.3  Med: -3.00 Max: 478.5
Current: 69.55
-1804.3
478.5
Current Ratio 2.96
NXTM's Current Ratio is ranked higher than
57% of the 191 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.64 vs. NXTM: 2.96 )
Ranked among companies with meaningful Current Ratio only.
NXTM' s Current Ratio Range Over the Past 10 Years
Min: 1.71  Med: 3.28 Max: 10.48
Current: 2.96
1.71
10.48
Quick Ratio 2.00
NXTM's Quick Ratio is ranked higher than
58% of the 191 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.70 vs. NXTM: 2.00 )
Ranked among companies with meaningful Quick Ratio only.
NXTM' s Quick Ratio Range Over the Past 10 Years
Min: 0.75  Med: 2.37 Max: 9.59
Current: 2
0.75
9.59
Days Inventory 76.70
NXTM's Days Inventory is ranked higher than
80% of the 188 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 127.92 vs. NXTM: 76.70 )
Ranked among companies with meaningful Days Inventory only.
NXTM' s Days Inventory Range Over the Past 10 Years
Min: 80.86  Med: 95.66 Max: 197.37
Current: 76.7
80.86
197.37
Days Sales Outstanding 27.36
NXTM's Days Sales Outstanding is ranked higher than
92% of the 162 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 63.57 vs. NXTM: 27.36 )
Ranked among companies with meaningful Days Sales Outstanding only.
NXTM' s Days Sales Outstanding Range Over the Past 10 Years
Min: 26.56  Med: 31.43 Max: 92.07
Current: 27.36
26.56
92.07
Days Payable 19.20
NXTM's Days Payable is ranked lower than
90% of the 161 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 55.85 vs. NXTM: 19.20 )
Ranked among companies with meaningful Days Payable only.
NXTM' s Days Payable Range Over the Past 10 Years
Min: 27.23  Med: 54.27 Max: 121.1
Current: 19.2
27.23
121.1

Valuation & Return

vs
industry
vs
history
Price/Net Current Asset Value 73.55
NXTM's Price/Net Current Asset Value is ranked lower than
95% of the 124 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 7.00 vs. NXTM: 73.55 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
NXTM' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 2.77  Med: 24.92 Max: 112.06
Current: 73.55
2.77
112.06
Price/Tangible Book 7.53
NXTM's Price/Tangible Book is ranked lower than
77% of the 167 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.11 vs. NXTM: 7.53 )
Ranked among companies with meaningful Price/Tangible Book only.
NXTM' s Price/Tangible Book Range Over the Past 10 Years
Min: 2.38  Med: 6.54 Max: 107.91
Current: 7.53
2.38
107.91
Price/Projected FCF 64.72
NXTM's Price/Projected FCF is ranked lower than
99% of the 89 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.93 vs. NXTM: 64.72 )
Ranked among companies with meaningful Price/Projected FCF only.
NXTM' s Price/Projected FCF Range Over the Past 10 Years
Min: 63.08  Med: 281.21 Max: 656.5
Current: 64.72
63.08
656.5
Price/Median PS Value 0.88
NXTM's Price/Median PS Value is ranked higher than
69% of the 166 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.10 vs. NXTM: 0.88 )
Ranked among companies with meaningful Price/Median PS Value only.
NXTM' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.24  Med: 0.98 Max: 3.81
Current: 0.88
0.24
3.81
Earnings Yield (Greenblatt) (%) -1.62
NXTM's Earnings Yield (Greenblatt) (%) is ranked lower than
67% of the 195 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.20 vs. NXTM: -1.62 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
NXTM' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: -89.8  Med: 0.00 Max: 0
Current: -1.62
-89.8
0

More Statistics

Revenue(Mil) $336
EPS $ -0.24
Beta-0.11
Short Percentage of Float7.13%
52-Week Range $13.47 - 22.60
Shares Outstanding(Mil)64.07

Business Description

Industry: Medical Instruments & Equipment » Medical Instruments & Supplies
Compare:XKLS:7153, SZSE:002432, ROCO:1565, NAS:ELGX, NAS:MMSI » details
Traded in other countries:N5X.Germany,
NxStage Medical Inc was incorporated in Delaware in 1998 under the name QB Medical, Inc., and later changed its name to NxStage Medical, Inc. NxStage is a medical device company that develops, manufactures and markets products for the treatment of kidney failure, fluid overload and related blood treatments and procedures. Its main product, the NxStage System One was designed to satisfy an unmet clinical need for a system that could deliver the therapeutic flexibility and clinical benefits associated with traditional dialysis machines in a smaller, portable, easy-to-use form that could be used by healthcare professionals and trained lay users alike in a number of settings, including patient homes, as well as more traditional care settings such as hospitals and dialysis clinics. Given its design, the System One is particularly well-suited for home hemodialysis and a range of dialysis therapies including more frequent, or 'daily,' dialysis. The System One is cleared by the United States Food and Drug Administration for home hemodialysis as well as hospital and clinic-based dialysis. It also sells needles and blood tubing sets mainly to dialysis clinics for the treatment of End Stage Renal Disease, or ESRD. The Company has two reporting segments, System One and In-Center. It distributes its products in three markets: the home, critical care and in-center. Within the System One segment, the Company sells and rentals System One and PureFlow SL equipment and sells disposable products in the home and critical care markets. The home market consists of dialysis centers that provide treatment options for patients that have ESRD, while the critical care market consists of hospitals or facilities that treat patients that have suddenly, and possibly temporarily, lost kidney function. The company sells essentially the same System One cyclers and disposables within each market and some of the company's largest customers in the home market provide outsourced renal dialysis services to hospitals in the critical care market to which the company sells System One cyclers and disposables. Sales of products to both markets are made through dedicated sales forces and products are distributed directly to the customer. Within the In-Center segment, the Company sells blood tubing sets and needles for hemodialysis primarily for the treatment of ESRD patients at dialysis centers and needles for apheresis. Nearly all In-Center products are sold through national distributors. The Company competes with Fresenius, Gambro, Nipro, Baxter International, Inc., or Baxter, JMS and others. The Company is subject to government regulation in the countries in which it conducts business. In the foreign countries in which the Company market and sell its products, it is subject to local regulations affecting, among other things, design and product standards, packaging and labeling and promotion requirements.
» More Articles for NAS:NXTM

Headlines

Articles On GuruFocus.com
Weekly 3-Year Low Highlights: MFLX, NXTM, CVRR, CMLP Nov 10 2013 
NxStage Medical Inc. (NXTM) President & CEO Jeffrey H Burbank sells 20,000 Shares Mar 18 2011 
NxStage Medical Inc. (NXTM) Sr. Vice President, CFO Robert S. Brown sells 15,000 Shares Mar 18 2011 
NxStage Medical Inc. (NXTM) Sr. Vice President, CFO Robert S. Brown sells 15,000 Shares Feb 18 2011 
NxStage Medical Inc. (NXTM) President & CEO Jeffrey H Burbank sells 20,000 Shares Feb 18 2011 
NxStage Medical Inc. (NXTM) President & CEO Jeffrey H Burbank sells 20,000 Shares Jan 21 2011 
NxStage Medical Inc. (NXTM) Sr. Vice President, CFO Robert S. Brown sells 15,000 Shares Jan 20 2011 
NxStage Medical Inc. (NXTM) President & CEO Jeffrey H Burbank sells 13,710 Shares Dec 17 2010 
NxStage Medical Inc. (NXTM) Sr. Vice President, CFO Robert S. Brown sells 12,000 Shares Dec 16 2010 
NxStage Medical Inc. (NXTM) President & CEO Jeffrey H Burbank sells 13,710 Shares Dec 16 2010 

More From Other Websites
NxStage Medical, Inc. :NXTM-US: Earnings Analysis: Q1, 2016 By the Numbers May 05 2016
Edited Transcript of NXTM earnings conference call or presentation 4-May-16 1:00pm GMT May 04 2016
NxStage Medical Inc Earnings Call scheduled for 9:00 am ET today May 04 2016
NXSTAGE MEDICAL, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial... May 04 2016
NxStage reports 1Q loss May 04 2016
NxStage reports 1Q loss May 04 2016
8:13 am Nxstage Medical beats by $0.03, slight beat on revs; guides Q2 revs above consensus; guides... May 04 2016
NxStage Reports First Quarter Financial Results May 04 2016
NxStage Reports First Quarter Financial Results May 04 2016
Q1 2016 NxStage Medical Inc Earnings Release - Before Market Open May 04 2016
NxStage to Present at the Deutsche Bank 41st Annual Health Care Conference Apr 25 2016
NxStage to Present at the Deutsche Bank 41st Annual Health Care Conference Apr 25 2016
NxStage Medical, Inc. – Value Analysis (NASDAQ:NXTM) : April 18, 2016 Apr 18 2016
ETF’s with exposure to NxStage Medical, Inc. : April 18, 2016 Apr 18 2016
NxStage Medical, Inc. breached its 50 day moving average in a Bullish Manner : NXTM-US : April 15,... Apr 15 2016
NxStage Kidney Care Opens New Dialysis Centers in Baltimore, Maryland Apr 12 2016
NxStage Kidney Care Opens New Dialysis Centers in Baltimore, Maryland Apr 12 2016
NxStage® to Report First Quarter 2016 Financial Results Apr 11 2016
National Donate Life Month: NxStage Teams Up with Organ Donation Nonprofit MatchingDonors.com Apr 07 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK